Systemic sclerosis [scleroderma] M34- >. ICD-10-CM Diagnosis Code P83.8 A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent...
Systemic sclerosis with lung involvement. M34.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM M34.81 became effective on October 1, 2019.
Systemic sclerosis, unspecified. Systemic disorder of the connective tissue; manifested by hardening and thickening of the skin, by abnormalities involving the microvasculature and larger vessels, and by fibrotic degenerative changes in various body organs including the heart, lungs, kidneys, and gastrointestinal tract.
The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement.
Systemic sclerosis is a rare chronic disease of unknown cause characterized by diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs (especially the esophagus, lower gastrointestinal tract, lungs, heart, and kidneys).
Progressive systemic sclerosis (PSS) is a generalized disorder of connective tissue characterized by inflammatory, fibrotic, and degenerative changes, accompanied by vascular lesions, in the skin (scleroderma), synovium, and certain internal organs, notably the esophagus, intestinal tract, heart, lung, and kidney.
Scleroderma (sklair-oh-DUR-muh), also known as systemic sclerosis, is a group of rare diseases that involve the hardening and tightening of the skin. It may also cause problems in the blood vessels, internal organs and digestive tract.
Systemic sclerosis is about 4 times more common among women than men. It is most common among people aged 20 to 50 and is rare in children.
Both MS and SS are autoimmune diseases. Whereas MS impacts only the central nervous system (CNS), SS can impact multiple organs and organ systems throughout the body. There are two types of SS: localized cutaneous SS, affecting only the skin, and diffuse SS, affecting both the skin and organs.
Progressive systemic sclerosis is an uncommon illness that causes excessive tissue fibrosis and vascular changes. It is often referred to as scleroderma, which more precisely is the skin thickening and fibrosis caused by the disease.
Prognosis of Systemic Sclerosis Sometimes systemic sclerosis worsens rapidly and becomes fatal (mainly with diffuse systemic sclerosis). At other times, it affects only the skin for decades before affecting internal organs, although some damage to internal organs (such as the esophagus) is almost inevitable.
Patients with limited cutaneous systemic sclerosis have a 10-year survival estimate of approximately 90%. However, development of interstitial lung disease (ILD) or pulmonary artery hypertension (PAH) dramatically increases the risk of death.
Systemic sclerosis can cause the tissues around joints to stiffen, which can reduce the range of movement of joints. It can also cause pain and swelling around affected joints.
Cutaneous involvement has 3 phases: (1) edematous, (2) indurative, and (3) atrophic. Skin becomes thickened and tight.
Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs.
Systemic sclerosis is diagnosed based on the presence of various symptoms above and physical examination findings. The diagnosis can be confirmed by the presence of certain autoantibodies in the blood as well as radiographic studies. Particularly, the ANA, or the antinuclear antibody test, is positive, but not always.
A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.
Systemic disorder of the connective tissue; manifested by hardening and thickening of the skin, by abnormalities involving the microvasculature and larger vessels, and by fibrotic degenerative changes in various body organs including the heart, lungs, kidneys, and gastrointestinal tract.
The 2022 edition of ICD-10-CM M34.9 became effective on October 1, 2021.
The 2021 edition of ICD-10-CM M34 became effective on October 1, 2020.
The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement.
Clinical Information. A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin.
The 2022 edition of ICD-10-CM M34 became effective on October 1, 2021.
The 2022 edition of ICD-10-CM M34.81 became effective on October 1, 2021.
A code also note instructs that 2 codes may be required to fully describe a condition but the sequencing of the two codes is discretionary, depending on the severity of the conditions and the reason for the encounter.
The ICD-10discharge diagnosis code M34.9 (Systemic sclerosis, unspecified) contributed the most confirmed SSc cases (30% [60 of 200]). The ICD-10discharge diagnosis code M34.8 (Other forms of systemic sclerosis) had the most false-positive results: 43.8% (7 of 16) of the excluded cases were from code M34.8.
One published14study reported that the accuracy of ICD-9codes for SSc (710.1 code) was 76% . In this study, the true positive cases were defined by the fulfillment of at least one of the three different classification criteria, including the updated 2013 ACR/EULAR criteria.10ICD-9 only has one code for SSc while ICD-10 has six, this difference could be an explanation why the accuracy may now be higher.
Our results suggest that using ICD-10codes alone to capture SSc is reliable in The French hospital database.
Studies assessing the accuracy of diagnosis coding by medical chart review are authorized by the National Commission of Information Technology and Liberty (CNIL: French Law on Privacy decision No. 89–117). All hospitalized patients in this hospital received written information on the possibility of such studies.
It is limited to a single tertiary center, not necessarily reflecting PMSI coding in the entire France. Even if coding rules are national, there may be differences between establishments. The generalizability of this study may be limited because there may be potential differences in coding in a contained healthcare system like Toulouse University Hospital compared with other systems where insurance approval is needed for medications, procedures, and treatments. Future studies will need to assess the accuracy of ICD-10codes for SSc in other settings.